Atossa Therapeutics (NASDAQ:ATOS) announces
a new drug development program called COVID-19 HOPE, which is an
acronym for AT-H201 in COVID-19 patients for Pulmonary Evaluation.
The program uses a novel combination of two
drugs approved by the FDA for other diseases to develop a therapy to
improve lung function and reduce the amount of time that COVID-19
patients are on ventilators.
Atossa has filed comprehensive provisional patent
applications related to AT-H201 and intends to apply to the FDA under
its Coronavirus Treatment Acceleration Program for approval to commence a
clinical study.
https://seekingalpha.com/news/3561298-atossa-rockets-103-on-launch-of-covidminus-19-hope-program
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.